10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
The European Commission (EC) has granted conditional marketing authorization for gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene). 4 June 2019
Germany’s Ethris, a leader in mRNA-based therapeutics, is expanding its leadership team by the addition of Thomas Langenickel in the role of chief medical officer. 4 June 2019
Bristol-Myers Squibb has announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) at the annual meeting of the American Society of Clinical Oncology (ASCO). 4 June 2019
Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen is definitely a contender at this year's event. 3 June 2019
Merck & Co’s industry-leading immuno-oncology drug Keytruda (pembrolizumab) is no stranger to making the headlines at ASCO, and this year’s meeting is no exception. 3 June 2019
Much awaited Phase III POLO trial data were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, and showed that Lynparza (olaparib) has a significant impact of progression of disease in certain pancreatic cancer patients. 3 June 2019
Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s isatuximab in a looming head-to-head with Johnson & Johnson’s Darzalex (daratumumab). 3 June 2019
Immunotherapy specialist Atara Biotherapeutics has presented clinical results relating to its biomarker research at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2019
New baseline biomarker analyses and updated clinical study efficacy and safety results were shared in a presentation, titled "Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214, bempeg), at the 2019 American Society of Clinical Oncology (ASCO) meeting in Chicago. 3 June 2019
Shares of Humanigen rose 8.7% to $1.24 by mid-morning today, after it revealed a clinical collaboration with Gilead Sciences’ subsidiary Kite to trial a combination of its flagship therapy in combination with one of the first CAR-T cell therapy to be approved by the US regulator. 31 May 2019
Japanese drug major Astellas Pharma today announced that the US Food and Drug Administration approved a supplemental New Drug Application (sNDA) to update the US product labeling for Xospata (gilteritinib) to include final analysis data from the ADMIRAL trial. 31 May 2019
Vertex Pharmaceuticals says it has selected the triple combination of the next-generation corrector VX-445 (elexacaftor), tezacaftor and ivacaftor to submit for potential global regulatory approvals for people ages 12 and older with cystic fibrosis (CF). 31 May 2019
Atara Biotherapeutics, a US biotech specializing in T-cell immunotherapies for cancer, has named Pascal Touchon its new president, chief executive. 30 May 2019
Inovio Pharmaceuticals regained much of the losses it suffered in the stock market on Wednesday, but the company’s share price was heading south again on Thursday. 30 May 2019
California clinical-stage biotech Inhibrx has entered into an agreement with privately held Italian drugmaker Chiesi Farmaceutici, granting the latter an option to exclusively license, develop and commercialize INBRX-101 outside of the USA and Canada effective upon a $10 million equity investment in Inhibrx. 30 May 2019
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Document for the use of Merck & Co’s Prevymis (letermovir/ID1153) in preventing cytomegalovirus (CMV) reactivation and disease in patients receiving an allogeneic stem cell transplant. 30 May 2019
The share price of Canadian biopharma Zymeworks (TSX: ZYME) closed 4% up on Wednesday after the company received two separate validations of its approach. 30 May 2019
USA-based private equity firm Ampersand Capital Partners announced plans to acquire Vibalogics GmbH, a German contract development and manufacturing organization (CDMO) focused on complex live biological products. 30 May 2019
German pharma major Boehringer Ingelheim and Danish biotech Gubra has announced a second collaboration and license agreement for the development of new poly-agonist peptides to treat obesity. 29 May 2019
Biomunex Pharmaceuticals, a privately-held French biotech focused on providing immuno-therapeutics through the discovery and development of bi- and multi-specific antibodies, has established a US subsidiary. 29 May 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024